TEVA Pharmaceutical Industries Limited: share-based compensation expense
TEVA Pharmaceutical Industries share-based compensation expense: $157.0 million for the year ending 2025-12-31, up 27.6% on the year. 19 values since 2007.
All TEVA Pharmaceutical Industries Limited financial histories
At a glance
TEVA Pharmaceutical Industries reported share-based compensation expense of $157.0 million for the year ending 2025-12-31, up 27.6% from $123.0 million a year earlier. From 2007 to 2025 it grew at a compound 4.8% a year, from $67.0 million to $157.0 million. Across the last five reported years it ranged from $119.0 million (2021-12-31) to $157.0 million (2025-12-31). That was 0.9% of revenue ($17.3 billion) for the same year.
Computed from the values in the table below, in USD; each links to the filing it came from.
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2007-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 157,000,000 | USD | 2026-02-03 | 10-K · 0001193125-26-034532 SEC |
| 2024-01-01 | 2024-12-31 | 123,000,000 | USD | 2026-02-03 | 10-K · 0001193125-26-034532 SEC |
| 2023-01-01 | 2023-12-31 | 121,000,000 | USD | 2026-02-03 | 10-K · 0001193125-26-034532 SEC |
| 2022-01-01 | 2022-12-31 | 124,000,000 | USD | 2025-02-05 | 10-K · 0001193125-25-020826 SEC |
| 2021-01-01 | 2021-12-31 | 119,000,000 | USD | 2024-02-12 | 10-K · 0001193125-24-031005 SEC |
| 2020-01-01 | 2020-12-31 | 129,000,000 | USD | 2023-02-10 | 10-K · 0001193125-23-031250 SEC |
| 2019-01-01 | 2019-12-31 | 119,000,000 | USD | 2022-02-09 | 10-K · 0001193125-22-032667 SEC |
| 2018-01-01 | 2018-12-31 | 155,000,000 | USD | 2021-02-10 | 10-K · 0001193125-21-036239 SEC |
| 2017-01-01 | 2017-12-31 | 133,000,000 | USD | 2020-02-21 | 10-K · 0001193125-20-044221 SEC |
| 2016-01-07 | 2016-12-31 | 124,000,000 | USD | 2019-02-19 | 10-K · 0001193125-19-043564 SEC |
| 2016-01-01 | 2016-12-31 | 124,000,000 | USD | 2018-02-12 | 10-K · 0001193125-18-039076 SEC |
| 2015-01-01 | 2015-12-31 | 117,000,000 | USD | 2018-02-12 | 10-K · 0001193125-18-039076 SEC |
| 2014-01-01 | 2014-12-31 | 95,000,000 | USD | 2017-02-15 | 20-F · 0001193125-17-045463 SEC |
| 2013-01-01 | 2013-12-31 | 64,000,000 | USD | 2016-02-11 | 20-F · 0001193125-16-459785 SEC |
| 2012-01-01 | 2012-12-31 | 82,000,000 | USD | 2015-02-09 | 20-F · 0001193125-15-039151 SEC |
| 2011-01-01 | 2011-12-31 | 91,000,000 | USD | 2014-02-10 | 20-F · 0001193125-14-041871 SEC |
| 2010-01-01 | 2010-12-31 | 80,000,000 | USD | 2013-02-12 | 20-F · 0001193125-13-050510 SEC |
| 2009-01-01 | 2009-12-31 | 54,000,000 | USD | 2012-02-17 | 20-F · 0001193125-12-067417 SEC |
| 2008-01-01 | 2008-12-31 | 63,000,000 | USD | 2011-02-15 | 20-F · 0001193125-11-036753 SEC |
| 2007-01-01 | 2007-12-31 | 67,000,000 | USD | 2010-02-22 | 20-F · 0001193125-10-036435 SEC |
Related TEVA PHARMACEUTICAL INDUSTRIES LIMITED histories
Inspect the source
- Entity
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED / CIK 0000818686
- Captured
- SEC response SHA-256
f2c93c1e5a25cb18cb0b293c07294b344882e3789d9edd47f98fdd8c904c6c6d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000818686.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))